Remedium Lifecare Ltd vs Samrat Pharmachem Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Remedium Lifecare Ltd is ₹ 0.39 as of 13 Apr 15:30 . The P/E Ratio of Remedium Lifecare Ltd is 36.4 as of March 2025 .The P/E Ratio of Samrat Pharmachem Ltd is 0 as of March 2025 . The Market Cap of Remedium Lifecare Ltd is ₹ 73.38 crore as of March 2025 .The Market Cap of Samrat Pharmachem Ltd is ₹ 0 crore as of March 2025 . The Revenue of Remedium Lifecare Ltd is ₹ 264.98 crore as of Mar '25 .The Revenue of Samrat Pharmachem Ltd is ₹ 0 crore as of Mar '25 . The EBITDA of Remedium Lifecare Ltd is ₹ 0.2 crore as of Mar '25 .The EBITDA of Samrat Pharmachem Ltd is ₹ 0 crore as of Mar '25 . The Net Profit of Remedium Lifecare Ltd is ₹ -2.05 crore as of Mar '25 .The Net Profit of Samrat Pharmachem Ltd is ₹ 0 crore as of Mar '25 . The Dividend Payout of Remedium Lifecare Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Samrat Pharmachem Ltd changed from 1.8 % on March 2022 to 4.35 % on March 2025 . This represents a CAGR of 24.68% over 4 years .

About Remedium Lifecare Ltd

Remedium Lifecare Limited (Formerly known as 'Roxy Exports Limited) was incorporated in February 19, 1988.
Consequent to change in the business activities and accordingly, in order to keep the name of the Company in consonance with the new business activities, the Company changed its name from 'Roxy Exports Limited' to 'Remedium Lifecare Limited' vide a fresh Certificate of Incorporation on November 6, 2020 issued by the Registrar of Companies. The Company being a pharmaceutical company is aligned across two business verticals viz. products and services.
Products business comprises trading and sale of APIs and Intermediates to innovator and generic pharmaceutical players in both domestic and international markets including the regulated markets. Apart from this, the Company is engaged in the business of trading in Advanced Pharmaceutical Intermediates, Active Pharmaceutical Ingredients (API's) and other pharma products used viz.

About Samrat Pharmachem Ltd

Samrat Pharmachem Limited was incorporated on June 16, 1992 at Ankleshwar in Gujarat led by the Promoters, Mr. Lalit Mehta & Mr. Rajesh Mehta.
Since then, it envisioned to focus on lodine Derivatives as their core products.
The Company's principal activities are manufacturing and selling chemicals.
Company is a producer of pharmaceutical chemicals.
The intermediates produced are used in pharmaceutical and chemical industries.

FAQs for the comparison of Remedium Lifecare Ltd and Samrat Pharmachem Ltd

Which company has a larger market capitalization, Remedium Lifecare Ltd or Samrat Pharmachem Ltd?

Market cap of Remedium Lifecare Ltd is 40 Cr while Market cap of Samrat Pharmachem Ltd is 65 Cr

What are the key factors driving the stock performance of Remedium Lifecare Ltd and Samrat Pharmachem Ltd?

The stock performance of Remedium Lifecare Ltd and Samrat Pharmachem Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Remedium Lifecare Ltd and Samrat Pharmachem Ltd?

As of May 4, 2026, the Remedium Lifecare Ltd stock price is INR ₹0.46. On the other hand, Samrat Pharmachem Ltd stock price is INR ₹211.1.

How do dividend payouts of Remedium Lifecare Ltd and Samrat Pharmachem Ltd compare?

To compare the dividend payouts of Remedium Lifecare Ltd and Samrat Pharmachem Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.